On 01/02/2025, Michael S. Brown, an executive at Regeneron Pharmaceuticals, was granted 166 shares of Common Stock at $0 per share. This transaction was reported as completed, increasing Brown's direct ownership to 1,548 shares.In addition to his direct holdings, Brown indirectly owns 11,162 shares through two trusts: 5,000 shares held by SLAT and 6,162 shares held by another trust. The total value of the granted shares was not disclosed in the filing.This stock grant appears to be part of Regeneron's executive compensation program, potentially aligning the executive's interests with those of shareholders. The transaction date of 01/02/2025 suggests it may be part of an annual award cycle.

On 01/02/2025, Michael S. Brown, an executive at Regeneron Pharmaceuticals, was granted 166 shares of Common Stock at $0 per share. This transaction was reported as completed, increasing Brown's direct ownership to 1,548 shares.In addition to his direct holdings, Brown indirectly owns 11,162 shares through two trusts: 5,000 shares held by SLAT and 6,162 shares held by another trust. The total value of the granted shares was not disclosed in the filing.This stock grant appears to be part of Regeneron's executive compensation program, potentially aligning the executive's interests with those of shareholders. The transaction date of 01/02/2025 suggests it may be part of an annual award cycle.